List view / Grid view

Acute myeloid leukaemia (AML)

Celyad posts an update on its NKR-2 Trial

30 March 2016 | By Victoria White

Celyad has announced the completion of the safety follow-up of the first patient in the third dose level in the Phase I/IIa of its NKR-2 T-cell therapy...

news

Celyad completes safety follow-up in the second dose level of patients in its NKR-2 trial

25 February 2016 | By Victoria White

The Phase I trial is designed to assess the safety and feasibility of NKR-2, in two different haematological indications...

news

FDA grants Breakthrough Therapy status to PKC412 (midostaurin)

19 February 2016 | By Victoria White

PKC412 (midostaurin) is an investigational treatment for adults with newly-diagnosed acute myeloid leukaemia who are FLT3 mutation-positive...

news

FDA grants third venetoclax Breakthrough Therapy Designation

28 January 2016 | By Victoria White

The designation is for venetoclax in combination with HMAs for the treatment of patients with untreated AML who are ineligible to receive standard induction therapy...

news

AML treatment market to reach $932.6 million by 2024

9 December 2015 | By Victoria White

The treatment market for acute myeloid leukaemia (AML) will rapidly expand in value from $342.7 million in 2014 to reach $932.6 million by 2024, says research and consulting firm GlobalData.

news

Astellas announces updated results for gilteritinib in AML

7 December 2015 | By Victoria White

This updated analysis of the Phase 1/2 study included 169 patients with FLT3 mutations who were treated with at least 80 mg gilteritinib (ASP2215)...

news

Second cohort of NKG2D CAR T-Cell Phase I Trial commences

2 December 2015 | By Victoria White

Celyad has announced the infusion of the first patient of the second cohort of its Phase I clinical trial evaluating it's NKG2D CAR T-Cell therapy in acute myeloid leukaemia and multiple myeloma...

news

EC approves Vidaza as a new treatment for elderly patients with AML

30 October 2015 | By Victoria White

Dr Hervé Dombret says the 'announcement brings hope to patients with AML, particularly the elderly and more frail patients who cannot undergo intensive therapies'...

news

First patient dosed in Phase 3 trial of gilteritinib in AML

28 October 2015 | By Victoria White

Gilteritinib has demonstrated inhibitory activity against FLT3 internal tandem duplication as well as tyrosine kinase domain, two common types of FLT3 mutations that are seen in AML...

news

CHMP adopts positive opinion of azacitidine for elderly patients with AML

25 September 2015 | By Victoria White

The CHMP adopted a positive opinion for an expanded indication of azacitidine for the treatment of adult patients aged 65 years or older with acute myeloid leukaemia who are not eligible for haematopoietic stem cell transplantation...

news

Astellas announces preliminary Phase 1/2 data for ASP2215 in patients with relapsed or refractory acute myeloid leukaemia

17 June 2015 | By Victoria White

Preliminary data from a Phase 1/2 trial on Astellas’ ASP2215 were presented at the European Haematology Association annual congress...

news

Tosedostat in combination with low dose cytarabine achieves primary endpoint in Phase 2 study

15 June 2015 | By Victoria White

CTI BioPharma has announced findings from a Phase 2 trial of tosedostat in combination with low dose cytarabine in patients with acute myeloid leukaemia...

news

Celyad completes 30-day safety follow-up of first patient in NKG2D Phase I trial

11 June 2015 | By Victoria White

Celyad has completed the 30-day safety follow-up of the first patient enrolled in a Phase I clinical trial evaluating the safety of NKG2D CAR T-cell therapy..

news

BerGenBio announces first patient dosed in BGB324 AML trial

5 November 2014 | By BerGenBio AS

BerGenBio AS announces that the first patient has been dosed in its multi-centre Phase 1b trial (BGBC003) of BGB324, a selective inhibitor of Axl, in patients with acute myeloid leukaemia (AML) at Haukeland University Hospital in Bergen, Norway...

news

Boehringer Ingelheim’s volasertib showed in a Phase II study an improvement in overall survival in older AML patients

9 July 2014 | By Boehringer Ingelheim

Results from a Phase II study, published in the American Society of Hematology journal Blood, showed patients with previously untreated acute myeloid leukemia aged 65 or older and ineligible for intensive remission induction therapy, lived longer...

Cookie	Description
cookielawinfo-checkbox-advertising-targeting	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID	This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged	This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.

Cookie	Description
cf_ob_info	This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob	This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only	This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush	This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db	This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC	This cookie is set by Youtube and is used to track the views of embedded videos.

Cookie	Description
bcookie	This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS	This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang	This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc	This cookie is set by LinkedIn and used for routing.
lissc	This cookie is set by LinkedIn share Buttons and ad tags.
vuid	We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId	This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule	This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session	This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues	This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga	This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat	This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid	This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.

Cookie	Description
advanced_ads_browser_width	This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions	This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info	This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer	This cookie is set by Advanced Ads and sets the referrer URL.
bscookie	This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE	This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr	This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory	This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE	This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.

Recommended

Acute myeloid leukaemia (AML)